关于 GDF-15 水平在原发性肝癌诊断和化疗效果评估中的价值研究。

Research on values of GDF-15 level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect.

机构信息

Department of Oncology, Eastern Hepatobiliary Hospital, The Second Military Medical University, Shanghai, P.R. China.

出版信息

Eur Rev Med Pharmacol Sci. 2018 Jun;22(12):3749-3754. doi: 10.26355/eurrev_201806_15255.

DOI:10.26355/eurrev_201806_15255

PMID:29949149

Abstract

OBJECTIVE

To investigate the values of growth differentiation factor-15 (GDF-15) level in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect.

PATIENTS AND METHODS

92 patients with liver cancer treated from June 2015 to May 2016 were selected as liver cancer group; 53 patients with benign liver lesion were selected as benign liver disease group, and 40 healthy subjects receiving physical examination were selected as healthy control group. Fasting venous blood was drawn from objects of study in the early morning at 1 d after admission and at the last day after chemotherapy (liver cancer group), and the serum GDF-15 level was measured.

RESULTS

The serum GDF-15 levels in patients in liver cancer group and benign liver disease group were significantly higher than those in healthy control group and benign liver disease group (p<0.05). The serum GDF-15 levels in patients with stage III and IV liver cancer were significantly higher than those in patients with stage I and II liver cancer, and the serum GDF-15 level in patients with stage IV liver cancer was significantly higher than that in patients with stage III liver cancer (p<0.05). There was no significant difference in serum GDF-15 level among patients with different clinical data (p>0.05). The ROC curve analysis showed that the threshold value of GDF-15 was 1573.23 ng/L, and the sensitivity, specificity, and accuracy were 81.23%, 83.99%, and 83.62%, respectively. The serum GDF-15 level in patients with progressive disease was significantly higher than those in patients with partial remission and stable disease, and the serum GDF-15 level in patients with stable disease was significantly higher than that in patients with partial remission (p<0.05).

CONCLUSIONS

The serum GDF-15 level has certain clinical values in the diagnosis of primary liver cancer and evaluation of chemotherapeutic effect.

摘要

目的

探讨生长分化因子 15（GDF-15）水平在原发性肝癌诊断及化疗效果评估中的价值。

方法

选取 2015 年 6 月至 2016 年 5 月收治的肝癌患者 92 例为肝癌组，选取同期良性肝脏病变患者 53 例为良性肝病组，另选取同期体检健康者 40 例为健康对照组。于入院后第 1 天及化疗结束前 1 天清晨空腹抽取各组研究对象静脉血，检测血清 GDF-15 水平。

结果

肝癌组、良性肝病组患者血清 GDF-15 水平均明显高于健康对照组及良性肝病组（P<0.05）；Ⅲ、Ⅳ期肝癌患者血清 GDF-15 水平明显高于Ⅰ、Ⅱ期肝癌患者，Ⅳ期肝癌患者血清 GDF-15 水平明显高于Ⅲ期肝癌患者（P<0.05）；不同临床资料患者血清 GDF-15 水平比较差异均无统计学意义（P>0.05）。ROC 曲线分析显示，GDF-15 的截断值为 1573.23 ng/L，其灵敏度、特异度、准确度分别为 81.23%、83.99%、83.62%。进展患者血清 GDF-15 水平明显高于部分缓解及稳定患者，稳定患者血清 GDF-15 水平明显高于部分缓解患者（P<0.05）。